Clinical trials: Adult Alveolar Soft Part Sarcoma
Advanced Solid Tumors, Triple Negative Breast Cancer
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
- Trial name
- NCT02936102
- Testing
- FAZ053, PDR001
- Where
- 12 sites in United States, Canada and 7 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals